Celularity (CELU) Common Equity (2018 - 2025)
Celularity (CELU) posted quarterly Common Equity of -$38.1 million for Q4 2025, down 530.71% year-over-year from $8.8 million in Q4 2024, and down 89.42% quarter-over-quarter from -$20.1 million in Q3 2025.
Celularity (CELU) Common Equity (2018 - 2025) Analysis & Trends
Celularity (CELU) has reported Common Equity for 8 consecutive years, with -$38.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 530.71% year-over-year to -$38.1 million; the TTM figure through Dec 2025 stood at -$38.1 million (down 530.71% YoY), while the FY2025 annual figure was -$38.1 million, down 530.71% from the prior year.
- Common Equity declined to -$38.1 million in Q4 2025 per CELU's latest filing, from -$20.1 million in the prior quarter.
- Across five years, Common Equity topped out at $198.9 million in Q4 2022 and bottomed at -$648.2 million in Q2 2021.
- Historically, Common Equity has averaged -$6.0 million across 5 years, with a median of $30.7 million in 2023.
- Annual changes were most pronounced in 2022 — Common Equity soared 123.16% — and 2025, when it slumped 530.71%.
- Celularity's Common Equity stood at $99.4 million in 2021, then surged by 100.07% to $198.9 million in 2022, then plunged by 79.41% to $41.0 million in 2023, then plunged by 78.43% to $8.8 million in 2024, then plunged by 530.71% to -$38.1 million in 2025.
- Business Quant data shows CELU's Common Equity at -$38.1 million in Q4 2025, -$20.1 million in Q3 2025, and -$25.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | -38.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -38.06 Mn |
| Sep 30, 2025 | -20.09 Mn |
| Jun 30, 2025 | -25.50 Mn |
| Mar 31, 2025 | -5.51 Mn |
| Dec 31, 2024 | 8.84 Mn |
| Sep 30, 2024 | 17.28 Mn |
| Jun 30, 2024 | 27.81 Mn |
| Mar 31, 2024 | 31.25 Mn |
| Dec 31, 2023 | 40.96 Mn |
| Sep 30, 2023 | 30.25 Mn |
| Jun 30, 2023 | 118.50 Mn |
| Mar 31, 2023 | 155.63 Mn |
| Dec 31, 2022 | 198.90 Mn |
| Sep 30, 2022 | 164.24 Mn |
| Jun 30, 2022 | 150.15 Mn |
| Mar 31, 2022 | 89.91 Mn |
| Dec 31, 2021 | 99.42 Mn |
| Sep 30, 2021 | 96.22 Mn |
| Jun 30, 2021 | -648.21 Mn |
| Mar 31, 2021 | -611.93 Mn |